Article
HDV Can Constrain HBV Genetic Evolution in HBsAg: Implications for the Identification of Innovative Pharmacological Targets.
Viruses - 9 Jul 2018
Colagrossi Luna, Salpini Romina, Scutari Rossana, Carioti Luca, Battisti Arianna, Piermatteo Lorenzo, Bertoli Ada, Fabeni Lavinia, Minichini Carmine, Trimoulet Pascale, Fleury Hervé, Nebuloso Elena, De Cristofaro Maria, Cappiello Giuseppina, Spanò Alberto, Malagnino Vincenzo, Mari Terenzio, Barlattani Angelo, Iapadre Nerio, Lichtner Miriam, Mastroianni Claudio, Lenci Ilaria, Pasquazzi Caterina, De Sanctis Giuseppe Maria, Galeota Lanza Alfonso, Stanzione Maria, Stornaiuolo Gianfranca, Marignani Massimo, Sarmati Loredana, Andreoni Massimo, Angelico Mario, Ceccherini-Silberstein Francesca, Perno Carlo-Federico, Coppola Nicola, Svicher Valentina
Abstract excerpt
Chronic HBV + HDV infection is associated with greater risk of liver fibrosis, earlier hepatic decompensation, and liver cirrhosis hepatocellular carcinoma compared to HBV mono-infection. However, to-date no direct anti-HDV drugs are available in clinical practice. Here, we identified conserved and variable regions in HBsAg and HDAg domains in HBV + HDV infection, a critical finding for the design of innovative...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
